Home
Billing codes
52284

PAYER POLICY CHANGES

52284 Insurance Policy Changes

CPT 52284, in plain terms, covers Cystoscopy in a male with mechanical dilation of a urethral stricture and drug delivery by a drug-coated balloon catheter, including fluoroscopy if used. CPT 52284 is referenced in 9 tracked payer policy changes from Regence BlueShield, Premera Blue Cross, and 5 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 52284 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Official descriptor: CPT 52284 on AAPC

Regence BlueShield · Effective Jan 1, 2027Medium impact
Devices for Treatment of Benign Prostatic Hyperplasia, Urethral Stricture, and Urethral Stenosis
Effective January 1, 2027, the Optilume Urethral Drug Coated Balloon may be considered medically necessary for recurrent anterior (bulbar) urethral stricture when the stricture is located in the anterior (bulbar) urethra, is 3 cm or less in length, and has failed prior endoscopic treatment such as direct visual internal urethrotomy or dilation. The Optilume Urethral Drug Coated Balloon is investigational when those criteria are not met, including penile urethral stricture, first-time treatment, and repeated use of the device. The temporarily implanted nitinol device (iTind), the Optilume BPH Catheter System, and the prostatic urethral scaffold (Zenflow Spring) are investigational for all indications.
Premera Blue Cross · Effective Nov 1, 2026High impact
Medical Policy and Coding Updates - November 2026
Premera Blue Cross (WA) published its November 2026 medical policy and coding update. Several changes take effect on different dates: Nov 1, Nov 6, Nov 15, Nov 16, 2026, Dec 3, 2026, Jan 1, 2027, and Feb 5, 2027, including new prior authorization/medical necessity review requirements for specific CPT/HCPCS codes (e.g., 33340, 31240, J1818, J9999, 52284, 17313–17315, 30117, 31242, 31243, S3600, S3601, C9762, C9763) and some codes now considered investigational or non-covered. Because the notice mixes past, current and future effective dates, the billing team should confirm applicability per date and per plan before acting.
Priority Health · Effective Jun 1, 2026High impact
May medical policy updates
Priority Health's May 2026 medical policy updates change coverage criteria across many medical policies. Most changes take effect June 1, 2026, and others take effect August 1, 2026, and both dates are before the analysis date of 2026-11-05, so these changes are historical and their current applicability should be checked before acting. Key changes include prior authorization being required for sacroiliac joint radiofrequency ablation, genicular nerve radiofrequency ablation for knee osteoarthritis, certain skin substitutes, and scar revision, and several procedures moving to not medically necessary.
Premera Blue Cross · Identified Nov 1, 2026High impact
Medical Policy and Coding Updates - November 2026
Premera's November 2026 Medical Policy and Coding Updates notice lists new, revised, deleted and renumbered medical policies, pharmacy policies and coding changes, with dates from November 1, 2026 through February 5, 2027. Several coding updates list codes that now require review for medical necessity and prior authorization, or are now considered investigational or non-covered. The notice also describes Carelon radiation oncology and genetic testing guideline updates effective November 15, 2026.
Independence Blue Cross · Effective Oct 1, 2026Medium impact
12.01.01bv, Experimental/Investigational Services
Independence Blue Cross added a long list of CPT, HCPCS and unlisted codes to its experimental/investigational list under commercial policy 12.01.01bv, which means these services are not covered under the medical benefit, retroactive to October 1, 2026. It also removed some codes from that list because they are now considered eligible (52284, 55868 and a brain catheter placement code) and moved basivertebral nerve ablation and bioengineered skin substitutes to other IBX policies. The notice lists CPT 64999 both as added (for the Avance nerve graft) and removed (for stereotactic brain catheter placement), so confirm that code with IBX before billing it.
Arkansas Blue Cross Blue Shield · Effective Apr 15, 2026Medium impact
Policy Criteria Change
Arkansas Blue Cross is changing CPT code 52284 from non-covered to restricted coverage under their Medical Technology Assessment policy. This means the procedure will now have coverage with certain restrictions rather than being completely excluded.
Excellus BlueCross BlueShield · Effective Oct 16, 2025Medium impact
Minimally Invasive Treatments for Benign Prostatic Hyperplasia (BPH) 7.01.104
Excellus BlueCross BlueShield policy 7.01.104 covers minimally invasive BPH treatments, including prostatic urethral lift, water vapor thermal therapy, Aquablation and prostate artery embolization, when symptomatic BPH is present and device-specific criteria are met, and it lists prostate artery embolization as changed from investigational to medically appropriate for specific indications in its October 16, 2025 update. Transperineal laser ablation, the temporary implantable nitinol device (iTIND) and drug-coated balloons such as Optilume are considered investigational. The policy history also records an 08/04/26 policy edit that updated the professional guidelines section to reflect the 2026 AUA update and changed the prostate artery embolization grade from C to B.
Aetna · Identified Oct 23, 2026Medium impact
Benign Prostatic Hyperplasia (CPB 0079, reviewed 2026-10-15)
Aetna's Clinical Policy Bulletin 0079 on benign prostatic hyperplasia (BPH), reviewed 2026-10-15, states that Aetna considers several treatments medically necessary for members with BPH as alternatives to transurethral resection of the prostate (TURP), including alpha adrenergic blockers, hormonal manipulation, laser-based procedures, Aquablation, prostatic urethral lift, prostatic arterial embolization and temporary implanted prostatic devices such as the iTind. It lists other approaches, such as absolute ethanol injection, botulinum toxin, high-intensity focused ultrasound, histotripsy and mirabegron, as experimental, investigational, or unproven, and it sets selection criteria and code-level coverage limits for several services.
Aetna · Identified Aug 12, 2026Medium impact
Benign Prostatic Hyperplasia (CPB 0079, reviewed 2026-04-15)
For benign prostatic hyperplasia (BPH), alpha blockers, finasteride, dutasteride, tadalafil (5 mg daily), prostatic urethral lift, prostatic arterial embolization, Aquablation, laser prostatectomy, TUVP, TUIP, TUMT and TUNA are medically necessary alternatives to transurethral resection of the prostate (TURP). Temporary implanted prostatic devices such as the iTind are medically necessary when prostate volume is between 25 and 75 g and there is no obstruction in the median lobe, and UroLume is medically necessary for men at least 60 years old, or under 60 and poor surgical candidates, whose prostates are at least 2.5 cm long. Absolute ethanol injection, botulinum toxin, cryosurgical ablation, high-intensity focused ultrasound, histotripsy, melatonin, mirabegron and phytotherapy are listed as experimental, investigational or unproven for BPH.

Watch 52284

Get one email when a payer policy names 52284, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

REFERENCE DATA

Payers with rules4

Payers requiring prior auth4

BCBS Michigan · Effective October 13, 2026
Prior authorization required in some cases
BCBSM and BCN procedure codes for which providers must request prior authorization (commercial lines)
Excellus BlueCross BlueShield · Effective October 1, 2026
Prior authorization required
Excellus BCBS utilization management standard clinical review preauthorization list
CalViva Health · Effective December 31, 2025
Prior authorization required
CalViva Health CMS-0057-F prior authorization requirements

FREQUENTLY ASKED QUESTIONS

Does BCBS Michigan require prior authorization for 52284?

BCBS Michigan lists 52284 on BCBSM and BCN procedure codes for which providers must request prior authorization (commercial lines) for commercial plans, with conditions (list dated October 13, 2026). Verify with the payer before scheduling.

Does CalViva Health require prior authorization for 52284?

CalViva Health lists 52284 on CalViva Health CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does Community Health Plan of Imperial Valley require prior authorization for 52284?

Community Health Plan of Imperial Valley lists 52284 on Community Health Plan of Imperial Valley CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does Excellus BlueCross BlueShield require prior authorization for 52284?

Excellus BlueCross BlueShield lists 52284 on Excellus BCBS utilization management standard clinical review preauthorization list for commercial plans (list dated October 1, 2026). Verify with the payer before scheduling.

What insurance policy changes affect CPT 52284?

There are 9 tracked policy changes affecting CPT 52284, including updates from Regence BlueShield, Premera Blue Cross, Priority Health. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 52284?

Payers that have issued tracked updates for CPT 52284 include: Regence BlueShield, Premera Blue Cross, Priority Health, Independence Blue Cross, Arkansas Blue Cross Blue Shield, Excellus BlueCross BlueShield, Aetna.

How do I get notified when CPT 52284 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 52284. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for CPT 52284?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

See every payer rule for 52284

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 52284 in one place.

See every payer rule

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Devices for Treatment of Benign Prostatic Hyperplasia, Urethral Stricture, and Urethral Stenosis

Medical Policy and Coding Updates - November 2026

May medical policy updates

Medical Policy and Coding Updates - November 2026

12.01.01bv, Experimental/Investigational Services

Policy Criteria Change

Minimally Invasive Treatments for Benign Prostatic Hyperplasia (BPH) 7.01.104

Benign Prostatic Hyperplasia (CPB 0079, reviewed 2026-10-15)

Benign Prostatic Hyperplasia (CPB 0079, reviewed 2026-04-15)

Prior authorization required in some cases

Prior authorization required